Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of V3V.DE is 7.5 and suggests 42% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell